These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 4905237)

  • 1. Reduction of toxicity in cancer chemotherapy.
    Perry S
    Cancer Res; 1969 Dec; 29(12):2319-25. PubMed ID: 4905237
    [No Abstract]   [Full Text] [Related]  

  • 2. Splenic embolization to prevent dose limitation of cancer chemotherapy.
    Lokich J; Costello P
    AJR Am J Roentgenol; 1983 Jan; 140(1):159-61. PubMed ID: 6600309
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy.
    Blumenthal RD; Lew W; Juweid M; Alisauskas R; Ying Z; Goldenberg DM
    Cancer; 2000 Jan; 88(2):333-43. PubMed ID: 10640965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New dimensions in the treatment of cancer?].
    Löwenberg B
    Ned Tijdschr Geneeskd; 1980 Mar; 124(10):337-9. PubMed ID: 6987542
    [No Abstract]   [Full Text] [Related]  

  • 6. [Toxic hematologic side effects of chemotherapy: nursing interventions].
    Schewski R
    Pflege Z; 2009 Aug; 62(8):466-9. PubMed ID: 19728437
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model.
    Neuwelt EA; Pagel MA; Hasler BP; Deloughery TG; Muldoon LL
    Cancer Res; 2001 Nov; 61(21):7868-74. PubMed ID: 11691805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of hematopoietic growth factors for high-dose chemotherapy and peripheral blood progenitor cell transplantation.
    Kanz L; Brugger W; Mertelsmann R
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):10-8. PubMed ID: 7528446
    [No Abstract]   [Full Text] [Related]  

  • 9. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection by amifostine of cyclophosphamide-induced myelosuppression.
    Alberts DS
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early suppressive effects of chemotherapy on recovery of bone marrow megakaryocyte precursors: possible relationship to platelet recovery.
    Warren MK; Zujewski J; Rose WL; Szabo JM; O'Shaughnessy JA; Halverson DC; Cowan KH; Gress RE; Schwartz GN
    Stem Cells; 1996; 14 Suppl 1():31-7. PubMed ID: 11012200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia].
    Sun XF; Guan ZZ; Huang H; Zhou QH; Yi C; Zhang LJ; Zhu J; Li R; Zhou J; Zhang M; Guo Y
    Ai Zheng; 2002 Aug; 21(8):892-5. PubMed ID: 12478901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of toxicities induced by chemotherapy in breast cancer patients.
    Mehreen L; Khanam A
    Biomed Pharmacother; 2005 Oct; 59(9):524-7. PubMed ID: 16154313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impedance effects of interleukin-6 on cyclophosphamide-induced hematopoietic damnification in dogs].
    Yin H; He X; Bao X; Liu X; Yang G
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Aug; 22(4):798-801. PubMed ID: 16156276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide regimens in rhesus monkey with and without marrow infusion.
    Storb R; Buckner CD; Dillingham LA; Thomas ED
    Cancer Res; 1970 Aug; 30(8):2195-203. PubMed ID: 4990004
    [No Abstract]   [Full Text] [Related]  

  • 17. [Dosage regimen optimization in cancer chemotherapy using a mathematical model].
    Barbolosi D; Freyer G; Ciccolini J; Iliadis A
    Bull Cancer; 2003 Feb; 90(2):167-75. PubMed ID: 12660135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of WR-151327: an orally active chemotherapy protector.
    Green D; Bensely D; Schein P
    Cancer Res; 1994 Feb; 54(3):738-41. PubMed ID: 8306335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical results of the associated use of a thymus extract (Leukotrophin) as an anti-leukopenic agent in radiotherapy and chemotherapy of neoplastic diseases].
    Banfi F; Ferrari M; Rusconi A
    Minerva Med; 1970 Sep; 61(72):3818-24. PubMed ID: 5454450
    [No Abstract]   [Full Text] [Related]  

  • 20. [Rooms free of pathogenic bacteria. Transfusion of autologous bone marrow and intensive chemotherapy].
    Schneider M
    Sem Ther; 1968 Apr; 44(4):259-61. PubMed ID: 4927218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.